(Q37118142)

18 August 2017

1 reference

title

The impact of T-cell immunity on ovarian cancer outcomes (English)

1 reference

18 August 2017

1 reference

Brad H Nelson

1

0 references

publication date

1 April 2008

1 reference

18 August 2017

Immunological Reviews

1 reference

18 August 2017

222

1 reference

18 August 2017

101-116

1 reference

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Standard treatment in advanced ovarian cancer in 2005: the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Ovarian cancer: epidemiology, biology, and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Lymphocytic infiltration and survival in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

PD-1 and its ligands in T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Cytokine-induced Killer Cells: NK-like T Cells with Cytotolytic Specificity against Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Interferon-gamma expression is an independent prognostic factor in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Interleukin-6 serum levels in patients with gynecological tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Immobilized MICA could expand human Vdelta1 gammadelta T cells in vitro that displayed major histocompatibility complex class I chain-related A-dependent cytotoxicity to human epithelial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Activation of Fas ligand/receptor system kills ovarian cancer cell lines by an apoptotic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor alpha (TNF-alpha).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

B7-H4 overexpression in ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Differential expression of interleukins IL-13 and IL-15 in normal ovarian tissue and ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Development of a syngeneic mouse model for events related to ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Cellular immunity in breast cancer patients completing taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

The immunological effects of taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Taxol Increases the Amount and T Cell–Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Standard treatments induce antigen-specific immune responses in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Immunologic approaches to ovarian cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00614.X

10.1111/J.1600-065X.2008.00614.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18363996